Monday, October 29, 2018 4:55:26 PM
“It was recently shown that motor neurons have the highest levels of Sig-1Rs in the central nervous system (CNS), and that Sig-1Rs may help direct the flow of ions through potassium channels [5]. This would be a way of reducing the excitability of motor neurons, therefore slowing the progression of ALS.”
From article by an author who co-authored the paper cited on slide 7 of our CTAD presentation. This was published in 2017 1 year after the one cited in the slide which was published in 2016.
The motor neurons also would apply to Parkinson’s as well as ALS, and dystonia as someone posted.
Here’s the 2017 article that states the above quote.
https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-017-0380-6
Here’s the original article link quoted and cited on slide 7 of the presentation
https://www.ncbi.nlm.nih.gov/m/pubmed/26869505/
This is the section quoted on the slide:
“The sigma-1 receptor (Sig-1R) is an endoplasmic reticulum (ER) protein that resides specifically in the mitochondria-associated endoplasmic reticulum (ER) membrane (MAM), an interface between ER and mitochondria. In addition to being able to translocate to the plasma membrane (PM) to interact with ion channels and other receptors, Sig-1R also occurs at the nuclear envelope, where it recruits chromatin-remodeling factors to affect the transcription of genes. Sig-1Rs have also been reported to interact with other membranous or soluble proteins at other loci, including the cytosol, and to be involved in several central nervous system (CNS) diseases. Here, we propose that Sig-1R is a pluripotent modulator with resultant multiple functional manifestations in living systems.”
Cite
https://www.ncbi.nlm.nih.gov/m/pubmed/26869505/
My narrative, not a quote, based on above:
The S1r is able to translocate (move) to the plasma membrane (PM) to interact with ion channels in order to “go to where problems in the mitochondria are” - specifically, they reside on the MAM (see above), but move around to problem areas (like a fire truck!) to address the problems (put them out).
So, if there are more S1r’s on motor neurons than other types of neurons (such as ones which control mood - affect depression, ones which affect memory and cognition - cause Alzheimer’s), less of the drug is needed to affect this highly populated area. Tons of receptors (entryways or binding sites) are going to receive the drug, as opposed to fewer open pathways in the memory and cognitive neurons which would need more drug to get in (fewer doors).
Further reason for lower dose necessary (from the transgenic mouse model research):
“Humans are very sensitive to most inflammatory stimuli, whereas mice are highly resistant to the very same stimuli. Indeed, mice are about 10,000-fold more resistant than humans to endotoxin, which is one of the most common pro-inflammatory bacterial toxins used to study inflammation. Unlike humans, mice tolerate millions of live bacteria in their blood before the induction of severe inflammation or shock.”
Cite
https://www.wired.co.uk/article/testing-drugs-on-mice
My narrative, not quote, based on above:
Therefore, due to much higher resistance to inflammation in mice than humans, much higher doses of inflammatory agents are necessary to get the same level of disease or infection and therefore higher doses of meds may be necessary to neutralize the stimuli.
In humans, it is not a 1 to 1 association of dose (based solely on weight).
Btw, outside the scope of this particular topic, but having to do with our drug’s superior performance in apoe gene AD participants, read the second article (2016 - the one used in the presentation on slide 7) to learn how S1r recruits chromatin remodeling factors at the nuclear envelope which affect the TRANSCRIPTION OF GENES.
Note: much more is actually known and understood about the S1r’s mechanism of action in the CNS than we give credit for. Certainly these disease states are complex, however, we have some powerful tools in our kit which we have been studying and understanding as well.
Finally, adding to our understanding in this complex but unraveling field:
An obligatory plug for the “home team” Pittsburgh Supercomputing Center:
“New imaging tools and technologies, like large-volume confocal fluorescence microscopy, have greatly accelerated neuroscience research in the past five years by allowing researchers to image large regions of the brain at such a high level of resolution that they can zoom in to the level of a single neuron or synapse, or zoom out to the level of the whole brain. These images, however, contain such a large amount of data that only a small part of one brain’s worth of data can be accessed at a time using a standard desktop computer. Additionally, images are often collected in different ways — at different resolutions, using different methodologies and different orientations. Comparing and combining data from multiple whole brains and datasets requires the power of supercomputing.”
Note: A SINGLE NEURON can be viewed! And we are establishing a data repository. Please read! Exciting news.
https://www.psc.edu/news-publications/2662-cmu-psc-pitt-building-brain-data-repository
GL to CNS scientists, patients, and investors,
Biostock
Recent AVXL News
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 03/22/2024 09:45:00 AM
- Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 03/18/2024 11:30:00 AM
- Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference • GlobeNewswire Inc. • 02/26/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:05:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:06 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/07/2024 09:31:07 PM
- Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/07/2024 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024 • GlobeNewswire Inc. • 02/01/2024 12:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:01:34 PM
- Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans • GlobeNewswire Inc. • 01/24/2024 12:30:00 PM
- Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 01/16/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 01:00:34 AM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM